Literature DB >> 6114837

Metabolism and disposition of naltrexone in man after oral and intravenous administration.

M E Wall, D R Brine, M Perez-Reyes.   

Abstract

The metabolism and elimination of [15, 16,-3H2]naltrexone was studied in man after oral and intravenous administration. The same metabolites, although in varying proportions, were observed in both cases; conjugated naltrexone and conjugated and unconjugated 6 beta-naltrexol were the major metabolites observed in plasma, urine, and feces. 2-Hydroxy-3-O-methyl-6 beta-naltrexol was found in minor quantities. Naltrexone was almost completely absorbed after oral administration. After oral and intravenous administration of naltrexone, about 60% of the dose was recovered in the urine in 48 and 72 hr, respectively. The route of administration did not significantly affect urinary clearance values obtained for unconjugated or conjugated naltrexone and 6 beta-naltrexol. The route of administration significantly affected terminal plasma half-life values obtained for unconjugated naltrexone (2.7 hr, iv; 8.9 hr, oral), but had little effect on comparable values obtained for total drug, conjugated naltrexone, and unconjugated and conjugated 6 beta-naltrexol. Combined gas chromatography-mass spectrometry was used to validate the presence of naltrexone, 6 beta-naltrexol, and 2-hydroxy-3-O-methyl-6 beta-naltrexol in urine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114837

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  28 in total

Review 1.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.

Authors:  Mikolaj Milewski; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2010-06-25       Impact factor: 4.200

4.  Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.

Authors:  Emmamuel O Akala; Pornruedee Wiriyacoonkasem; Gaofeng Pan
Journal:  Drug Dev Ind Pharm       Date:  2011-03-30       Impact factor: 3.225

5.  Evaluation of the counter-regulatory responses to hypoglycaemia in patients with type 1 diabetes during opiate receptor blockade with naltrexone.

Authors:  Sarita Naik; Renata Belfort-DeAguiar; Anne-Sophie Sejling; Barbara Szepietowska; Robert S Sherwin
Journal:  Diabetes Obes Metab       Date:  2017-02-17       Impact factor: 6.577

Review 6.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

7.  Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles.

Authors:  Wusheng Yin; Emmanuel O Akala; Robert E Taylor
Journal:  Int J Pharm       Date:  2002-09-05       Impact factor: 5.875

8.  Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs.

Authors:  M A Hussain; E Shefter
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

Review 9.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.